Cargando…

Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives

Iron is a micronutrient essential for cellular energy and metabolism, necessary for maintaining body homoeostasis. Iron deficiency is an important co-morbidity in patients with heart failure (HF). A major factor in the pathogenesis of anaemia, it is also a separate condition with serious clinical co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jankowska, Ewa A., von Haehling, Stephan, Anker, Stefan D., Macdougall, Iain C., Ponikowski, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596759/ https://www.ncbi.nlm.nih.gov/pubmed/23100285 http://dx.doi.org/10.1093/eurheartj/ehs224

Ejemplares similares

Iron Deficiency in Heart Failure: A Korea-Oriented Review
por: Jankowska, Ewa A., et al.
Publicado: (2023)

Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners
por: Drozd, Marcin, et al.
Publicado: (2016)

Iron deficiency as energetic insult to skeletal muscle in chronic diseases
por: Dziegala, Magdalena, et al.
Publicado: (2018)

Iron Deficiency and Deranged Myocardial Energetics in Heart Failure
por: Tkaczyszyn, Michał, et al.
Publicado: (2022)

Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure
por: Tkaczyszyn, Michał, et al.
Publicado: (2021)

Iron deficiency and cardiovascular disease
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure
por: Cvan Trobec, Katja, et al.
Publicado: (2015)

Iron deficiency in heart failure
por: Loncar, Goran, et al.
Publicado: (2021)

Monitoring of iron status in patients with heart failure
por: Jankowska, Ewa A, et al.
Publicado: (2019)

Iron Deficiency in Heart Failure: A Practical Guide
por: Ebner, Nicole, et al.
Publicado: (2013)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Why is Iron Deficiency Recognised as an Important Comorbidity in Heart Failure?
por: Ebner, Nicole, et al.
Publicado: (2019)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure
por: Rozentryt, Piotr, et al.
Publicado: (2015)

Iron Deficiency and Reduced Muscle Strength in Patients with Acute and Chronic Ischemic Stroke
por: Scherbakov, Nadja, et al.
Publicado: (2022)

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
por: McDonagh, Theresa, et al.
Publicado: (2015)

Heart failure in the last year: progress and perspective
por: Tomasoni, Daniela, et al.
Publicado: (2020)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency
por: Macdougall, Iain C., et al.
Publicado: (2012)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023)

Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure
por: Doehner, Wolfram, et al.
Publicado: (2015)

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF
por: McEwan, Phil, et al.
Publicado: (2021)

Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?
por: Tkaczyszyn, Michał, et al.
Publicado: (2023)

ESC Heart Failure increases its impact factor
por: Anker, Markus S., et al.
Publicado: (2020)

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency
por: Anker, Stefan D., et al.
Publicado: (2022)

Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1
por: Jankowska, Ewa A., et al.
Publicado: (2011)

Iron status, catabolic/anabolic balance, and skeletal muscle performance in men with heart failure with reduced ejection fraction
por: Tkaczyszyn, Michał, et al.
Publicado: (2021)

Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Iron deficiency is related to low functional outcome in patients at early rehabilitation after acute stroke
por: Doehner, Wolfram, et al.
Publicado: (2022)

Drug therapy in elderly heart failure patients
por: Jankowska, Ewa A, et al.
Publicado: (2019)

Leukocyte Redistribution: Effects of Beta Blockers in Patients with Chronic Heart Failure
por: von Haehling, Stephan, et al.
Publicado: (2009)

Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK
por: Gutzwiller, Florian S., et al.
Publicado: (2012)

Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)
por: von Haehling, Stephan, et al.
Publicado: (2010)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure
por: Tkaczyszyn, Michał, et al.
Publicado: (2018)

Creating an impact, not an impression: ESC Heart Failure in its seventh year
por: von Haehling, Stephan, et al.
Publicado: (2021)

Structural and functional abnormalities in iron-depleted heart
por: Kobak, Kamil A, et al.
Publicado: (2018)

Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients
por: Martin‐Malo, Alejandro, et al.
Publicado: (2019)

Open access efforts begin to bloom: ESC Heart Failure gets full attention and first impact factor
por: Anker, Stefan D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h4qr3b60rc9kn4qqjmjk9vmf31